Neurological
Glioblastoma
PATSGO: Randomized Multicentric Phase II Study of Prolonged Adjuvant Temozolomide or "Stop and Go" in Glioblastoma Patients .
- Study Phase II
- Selection criteria
Glioblastoma
A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of AZD2171 (RECENTIN) Monotherapy and Combination of AZD2171 with Lomustine to the Efficacy of Lomustine Alone.
- Study Phase III
- Selection criteria
Low grade glioma
Evaluating primary chemotherapy with Temozolomide vs Radiotherapy in patients with low grade gliomas after stratification for genetic 1p/19q loss: a phase III study.
- Study Phase III
- Selection criteria
Glioblastoma
Phase III trial on concurrent and adjuvant temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON intergroup trial.
- Study Phase III
- Selection criteria
Glioblastoma
A Multi-Centre,Open-Label Controlled, Phase III Study, Testing Cilengitide in Combination with Standard treatment Versus Standard Treatment Alone: CENTRIC study
- Study Phase III
- Selection criteria